Pet Cancer 2019: A Developing Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pet Cancer 2019: A Developing Market” report has been added to ResearchAndMarkets.com’s offering.

The pet market is growing at a dramatic rate with health care products and services comprising a significant portion of the expenditure on pets. This will likely increase as pet life spans lengthen and the pet population ages.

This important report reviews the diverse research & development (R&D) approaches currently employed in the rapidly developing global market for pet cancer products and services. It covers current trends in veterinary oncology, including regulatory strategies, chemotherapies, immunotherapies, diagnostics and complementary approaches.

Key Insights

• Overview of pet cancer
• Companies active in the market
• Regulatory hurdles & strategies
• Chemotherapeutics

Topics Covered

Executive Summary

Chapter 1: Introduction

1.1 The Animal Health Industry

1.2 The Companion Animal Sector

1.2.1. Changes in Pet Ownership

– Pet Ownership in the USA

– Pet Ownership in Europe

1.2.2. The Future of Companion Animal Health in Developed Markets

1.3 Summary

Chapter 2: Pet Cancer – Factors Influencing the Market

2.1 Overview

2.2 Translation of Pet Cancer Research to Human Health

2.3 Owner Perceptions of Cancer in their Pet

2.4 Factors Influencing Owners Decisions in Relation to Chemotherapy

2.5 Owners Concerns During Treatment of their Pet for Cancer

2.6 Owner Perceptions of Radiotherapy

2.7 Assessment of Quality of Life in Pets Receiving Cancer Treatment

2.8 Vet Perceptions of Cancer Treatment of Pets

2.9 Cancer Clinical Trials

2.10 A Holistic Approach

2.11 Supporting organisations

Chapter 3: The Animal Health Companies Cited in this Report

Overview

3.1 AB Science

3.2 Anivive Lifesciences

3.3 Aratana Therapeutics

3.4 ARK Animal Health

3.5 Assisi Research Laboratories

3.6 EirGen Pharma

3.7 Elanco

3.8 ELIAS Animal Health

3.9 Jaguar (Animal) Health

3.10 Karyopharm Therapeutics

3.11 Man’s Best Friends Therapeutics

3.12 Merial/Boehringer Ingelheim

3.13 Novavive

3.14 Nuovo Biologics

3.15 Ogenx Therapeutics Corporation

3.16 Osamia Pharmaceutical

3.17 PharmAust

3.18 QBiotics

3.19 Rhizen Pharmaceuticals

3.20 Torigen Pharma

3.21 Veiove Animal Health

3.22 Vet DC

3.23 Virbac

3.24 Zoetis

Chapter 4: Regulation of Pet Cancer Products

4.1 The United States (US) and European (EU) Regulatory Authorities

4.2 Regulatory Guidance

4.3 Availability of Pet Cancer Medicines and Vaccines

4.4 Use of Unlicensed Medicinal Products

Chapter 5: Pet Cancer – Incidence

5.1 Overview

5.2 Pet Cancer Incidence

5.3 Types and Locations of Pet Cancer

5.4 Overall conclusion on the incidence and prevalence of cancer in pets

Chapter 6: Pet Cancer – Current Management Modalities for common tumours

6.1 Mast Cell Tumours

6.2 Mammary tumours

6.3 Melanoma

6.4 Lymphoma

6.5 Injection site sarcoma/fibrosarcoma

6.6 Squamous cell carcinoma

6.7 Osteosarcoma

Chapter 7: Pet Cancer Pharmaceuticals

7.1 Overview

7.2 Palladia (Zoetis)

7.3 Masivet (AB Science)

7.4 Tanovea-CA1 (VetDC)

7.5 Paccal Vet-CA1 (Osamia)

7.6 Pet Cancer Pharmaceuticals in Development

– Doxophos Vet (Osamia)

– Tigilanol tiglate (QBiotics/Virbac)

– Verdinexor (Anivive Lifesciences)

– RC-2b geroxane (Ogenx Therapeutics Corporation)

– Asparaginase (Assisi Research Laboratories)

– Resiniferatoxin (ARK Animal Health)

– SP-SAP: Substance P & Saporin (Veiove Animal Health)

– RV1001, PI3K inhibitor (Rhizen Pharmaceutical)

– Chlorambucil (EirGen Pharma)

– Canalevia (Jaguar Animal Health)

– Dactinomycin (Assisi Research Laboratories)

7.7 Other Potential Pet Cancer Products

Chapter 8: Pet Cancer Immunologicals

8.1 Overview

8.2 Oncept Canine Melanoma Vaccine DNA (Merial/Boehringer Ingelheim)

8.3 Oncept IL-2 (Merial/Boehringer Ingelheim)

8.4 Immunocidin (Novavive)

8.5 Pet Cancer Immunotherapies in Development

– Osteosarcoma vaccine (Aratana Therapeutics)

– Torigen Pharma

– ELIAS Cancer Immunotherapy: ECI (Elias Animal Health)

– Prophylactic Vaccine Project

– Man’s Best Friends Therapeutics (MBFT)

– Summary

– References

List of Figures

Figure 1: Percentage of European Households owning at least one cat or one dog

Figure 2: Pet age in human years

Figure 3: Holistic approach

Figure 4: Feline fibrosarcoma

Figure 5: Canine mammary tumour

Figure 6: Canine osteosarcoma

Figure 7: Mast Cell Tumours

Figure 8: Mammary Tumours

Figure 9: Canine Oral Melanoma

Figure 10: Feline Ocular Melanoma

Figure 11: Canine lymphoma

Figure 12: Feline lymphoma

Figure 13: Feline fibrosarcoma

Figure 14: Canine Squamous cell carcinoma

Figure 15: Feline Squamous cell carcinoma (extremities)

Figure 16: Feline Squamous cell carcinoma (oral)

Figure 17: Canine Osteosarcoma

Figure 18: Feline Osteosarcoma

Figure 19: Palladia

Figure 20: Masivet

Figure 21: Tanovea-CA1

Figure 22: Paccal Vet-CA-1

Figure 23: VET JET system

Figure 24: Oncept IL-2

Figure 25: Immunocidin

List of Tables

Table 1: Top ten dog and cat ownership countries in the EU in 2017

Table 2: Anti-cancer guidelines issued by the EMA and FDA CVM

Table 3: CVM designations with a canine cancer indication

Table 4: Summary of Veterinary Cancer Registries (Active and Dormant)

Table 5: Incidence of Canine Cancer in Developed Countries

Table 6: Incidence of Feline Cancer in Developed Countries

Table 7: Common Anatomical Locations for Canine Cancer

Table 8: Common Anatomical Locations for Feline Cancer

For more information about this report visit https://www.researchandmarkets.com/r/hemxqs

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics: Oncology Drugs, Animal Pharmaceuticals